Toxic epidermal necrolysis (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Toxic epidermal necrolysis" in English language version.

refsWebsite

Global rank English rank

24nih.gov

4^th place

18doi.org

2^nd place

6web.archive.org

1^st place

5semanticscholar.org

11^th place

8^th place

2worldcat.org

5^th place

1orpha.net

3,537^th place

7,177^th place

1uzh.ch

3,633^rd place

3,091^st place

1emedicine.com

3,595^th place

3,333^rd place

1cochrane.org

7,609^th place

low place

cochrane.org

Majumdar S, Mockenhaupt M, Roujeau JC, Townshend AP (2002-10-21). "Interventions for toxic epidermal necrolysis". Cochrane Database of Systematic Reviews. 2015 (4): CD001435. doi:10.1002/14651858.CD001435. ISSN 1465-1858. PMC 8958873. PMID 12519556. Archived from the original on 2018-06-25. Retrieved 2018-06-25.

doi.org

Adler NR, Aung AK, Ergen EN, Trubiano J, Goh MS, Phillips EJ (2017). "Recent advances in the understanding of severe cutaneous adverse reactions". The British Journal of Dermatology. 177 (5): 1234–1247. doi:10.1111/bjd.15423. PMC 5582023. PMID 28256714.
Schwartz RA, McDonough PH, Lee BW (August 2013). "Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis". Journal of the American Academy of Dermatology. 69 (2): 173.e1–13, quiz 185–6. doi:10.1016/j.jaad.2013.05.003. PMID 23866878.
Schwartz RA, McDonough PH, Lee BW (August 2013). "Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment". Journal of the American Academy of Dermatology. 69 (2): 187.e1–16, quiz 203–4. doi:10.1016/j.jaad.2013.05.002. PMID 23866879.
Jordan MH, Lewis MS, Jeng JG, Rees JM (1991). "Treatment of toxic epidermal necrolysis by burn units: another market or another threat?". The Journal of Burn Care & Rehabilitation. 12 (6): 579–81. doi:10.1097/00004630-199111000-00015. PMID 1779014.
Roujeau JC, Stern RS (10 November 1994). "Severe adverse cutaneous reactions to drugs". The New England Journal of Medicine. 331 (19): 1272–85. doi:10.1056/nejm199411103311906. PMID 7794310.
Morales ME, Purdue GF, Verity SM, Arnoldo BD, Blomquist PH (October 2010). "Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN". American Journal of Ophthalmology. 150 (4): 505–510.e1. doi:10.1016/j.ajo.2010.04.026. PMID 20619392.
Maverakis E, Wang EA, Shinkai K, Mahasirimongkol S, Margolis DJ, Avigan M, Chung WH, Goldman J, Grenade LL (2017-06-01). "Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Standard Reporting and Evaluation Guidelines: Results of a National Institutes of Health Working Group" (PDF). JAMA Dermatology. 153 (6): 587–592. doi:10.1001/jamadermatol.2017.0160. ISSN 2168-6068. PMID 28296986. S2CID 205110875. Archived (PDF) from the original on 2019-12-03. Retrieved 2019-12-12.
DeMers G, Meurer, WJ, Shih, R, Rosenbaum, S, Vilke, GM (December 2012). "Tissue plasminogen activator and stroke: review of the literature for the clinician". The Journal of Emergency Medicine. 43 (6): 1149–54. doi:10.1016/j.jemermed.2012.05.005. PMID 22818644.
Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, Hu SL, Wu MT, Chen GS, Wong TW, Hsiao PF, Chen WH, Shih HY, Fang WH, Wei CY, Lou YH, Huang YL, Lin JJ, Chen YT (April 2006). "Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions". Pharmacogenetics and Genomics. 16 (4): 297–306. doi:10.1097/01.fpc.0000199500.46842.4a. PMID 16538176. S2CID 45667604.
McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperavičiūtė D, Carrington M, Sills GJ, Marson T, Jia X, de Bakker PI, Chinthapalli K, Molokhia M, Johnson MR, O'Connor GD, Chaila E, Alhusaini S, Shianna KV, Radtke RA, Heinzen EL, Walley N, Pandolfo M, Pichler W, Park BK, Depondt C, Sisodiya SM, Goldstein DB, Deloukas P, Delanty N, Cavalleri GL, Pirmohamed M (24 March 2011). "HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans". The New England Journal of Medicine. 364 (12): 1134–43. doi:10.1056/nejmoa1013297. PMC 3113609. PMID 21428769.
Tohkin M, Kaniwa N, Saito Y, Sugiyama E, Kurose K, Nishikawa J, Hasegawa R, Aihara M, Matsunaga K, Abe M, Furuya H, Takahashi Y, Ikeda H, Muramatsu M, Ueta M, Sotozono C, Kinoshita S, Ikezawa Z, Japan Pharmacogenomics Data Science C (February 2013). "A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients". The Pharmacogenomics Journal. 13 (1): 60–9. doi:10.1038/tpj.2011.41. PMID 21912425. S2CID 42286060.
Alfirevic A, Pirmohamed M, Marinovic B, Harcourt-Smith L, Jorgensen AL, Cooper TE (17 July 2019). "Genetic testing for prevention of severe drug-induced skin rash". Cochrane Database of Systematic Reviews. 2019 (7): CD010891. doi:10.1002/14651858.CD010891.pub2. PMC 6636675. PMID 31314143.
Schwartz RA, McDonough PH, Lee BW (Aug 2013). "Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment". Journal of the American Academy of Dermatology. 69 (2): 187.e1–16, quiz 203–4. doi:10.1016/j.jaad.2013.05.002. PMID 23866879.
Zajicek R, Pintar D, Broz L, Suca H, Königova R (May 2012). "Toxic epidermal necrolysis and Stevens-Johnson syndrome at the Prague Burn Centre 1998-2008". Journal of the European Academy of Dermatology and Venereology. 26 (5): 639–43. doi:10.1111/j.1468-3083.2011.04143.x. PMID 21668825. S2CID 25253929.
Rajaratnam R, Mann C, Balasubramaniam P, et al. (December 2010). "Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centre". Clin. Exp. Dermatol. 35 (8): 853–62. doi:10.1111/j.1365-2230.2010.03826.x. PMID 20456393. S2CID 1477097.
Majumdar S, Mockenhaupt M, Roujeau JC, Townshend AP (2002-10-21). "Interventions for toxic epidermal necrolysis". Cochrane Database of Systematic Reviews. 2015 (4): CD001435. doi:10.1002/14651858.CD001435. ISSN 1465-1858. PMC 8958873. PMID 12519556. Archived from the original on 2018-06-25. Retrieved 2018-06-25.
Quinn AM, Brown K, Bonish BK, Curry J, Gordon KB, Sinacore J, Gamelli R, Nickoloff BJ, et al. (2005). "Uncovering histological criteria with prognostic significance in toxic epidermal necrolysis". Arch Dermatol. 141 (6): 683–7. doi:10.1001/archderm.141.6.683. PMID 15967913.
Schwartz RA, McDonough, PH, Lee, BW (August 2013). "Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment". Journal of the American Academy of Dermatology. 69 (2): 187.e1–16, quiz 203–4. doi:10.1016/j.jaad.2013.05.002. PMID 23866879.

emedicine.com

Garra, GP (2007). "Toxic Epidermal Necrolysis Archived 2007-12-27 at the Wayback Machine". Emedicine.com. Retrieved on December 13, 2007.

nih.gov

pubmed.ncbi.nlm.nih.gov

Adler NR, Aung AK, Ergen EN, Trubiano J, Goh MS, Phillips EJ (2017). "Recent advances in the understanding of severe cutaneous adverse reactions". The British Journal of Dermatology. 177 (5): 1234–1247. doi:10.1111/bjd.15423. PMC 5582023. PMID 28256714.
Schwartz RA, McDonough PH, Lee BW (August 2013). "Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis". Journal of the American Academy of Dermatology. 69 (2): 173.e1–13, quiz 185–6. doi:10.1016/j.jaad.2013.05.003. PMID 23866878.
Schwartz RA, McDonough PH, Lee BW (August 2013). "Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment". Journal of the American Academy of Dermatology. 69 (2): 187.e1–16, quiz 203–4. doi:10.1016/j.jaad.2013.05.002. PMID 23866879.
Jordan MH, Lewis MS, Jeng JG, Rees JM (1991). "Treatment of toxic epidermal necrolysis by burn units: another market or another threat?". The Journal of Burn Care & Rehabilitation. 12 (6): 579–81. doi:10.1097/00004630-199111000-00015. PMID 1779014.
Roujeau JC, Stern RS (10 November 1994). "Severe adverse cutaneous reactions to drugs". The New England Journal of Medicine. 331 (19): 1272–85. doi:10.1056/nejm199411103311906. PMID 7794310.
Morales ME, Purdue GF, Verity SM, Arnoldo BD, Blomquist PH (October 2010). "Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN". American Journal of Ophthalmology. 150 (4): 505–510.e1. doi:10.1016/j.ajo.2010.04.026. PMID 20619392.
Maverakis E, Wang EA, Shinkai K, Mahasirimongkol S, Margolis DJ, Avigan M, Chung WH, Goldman J, Grenade LL (2017-06-01). "Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Standard Reporting and Evaluation Guidelines: Results of a National Institutes of Health Working Group" (PDF). JAMA Dermatology. 153 (6): 587–592. doi:10.1001/jamadermatol.2017.0160. ISSN 2168-6068. PMID 28296986. S2CID 205110875. Archived (PDF) from the original on 2019-12-03. Retrieved 2019-12-12.
DeMers G, Meurer, WJ, Shih, R, Rosenbaum, S, Vilke, GM (December 2012). "Tissue plasminogen activator and stroke: review of the literature for the clinician". The Journal of Emergency Medicine. 43 (6): 1149–54. doi:10.1016/j.jemermed.2012.05.005. PMID 22818644.
Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, Hu SL, Wu MT, Chen GS, Wong TW, Hsiao PF, Chen WH, Shih HY, Fang WH, Wei CY, Lou YH, Huang YL, Lin JJ, Chen YT (April 2006). "Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions". Pharmacogenetics and Genomics. 16 (4): 297–306. doi:10.1097/01.fpc.0000199500.46842.4a. PMID 16538176. S2CID 45667604.
McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperavičiūtė D, Carrington M, Sills GJ, Marson T, Jia X, de Bakker PI, Chinthapalli K, Molokhia M, Johnson MR, O'Connor GD, Chaila E, Alhusaini S, Shianna KV, Radtke RA, Heinzen EL, Walley N, Pandolfo M, Pichler W, Park BK, Depondt C, Sisodiya SM, Goldstein DB, Deloukas P, Delanty N, Cavalleri GL, Pirmohamed M (24 March 2011). "HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans". The New England Journal of Medicine. 364 (12): 1134–43. doi:10.1056/nejmoa1013297. PMC 3113609. PMID 21428769.
Tohkin M, Kaniwa N, Saito Y, Sugiyama E, Kurose K, Nishikawa J, Hasegawa R, Aihara M, Matsunaga K, Abe M, Furuya H, Takahashi Y, Ikeda H, Muramatsu M, Ueta M, Sotozono C, Kinoshita S, Ikezawa Z, Japan Pharmacogenomics Data Science C (February 2013). "A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients". The Pharmacogenomics Journal. 13 (1): 60–9. doi:10.1038/tpj.2011.41. PMID 21912425. S2CID 42286060.
Alfirevic A, Pirmohamed M, Marinovic B, Harcourt-Smith L, Jorgensen AL, Cooper TE (17 July 2019). "Genetic testing for prevention of severe drug-induced skin rash". Cochrane Database of Systematic Reviews. 2019 (7): CD010891. doi:10.1002/14651858.CD010891.pub2. PMC 6636675. PMID 31314143.
Schwartz RA, McDonough PH, Lee BW (Aug 2013). "Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment". Journal of the American Academy of Dermatology. 69 (2): 187.e1–16, quiz 203–4. doi:10.1016/j.jaad.2013.05.002. PMID 23866879.
Zajicek R, Pintar D, Broz L, Suca H, Königova R (May 2012). "Toxic epidermal necrolysis and Stevens-Johnson syndrome at the Prague Burn Centre 1998-2008". Journal of the European Academy of Dermatology and Venereology. 26 (5): 639–43. doi:10.1111/j.1468-3083.2011.04143.x. PMID 21668825. S2CID 25253929.
Rajaratnam R, Mann C, Balasubramaniam P, et al. (December 2010). "Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centre". Clin. Exp. Dermatol. 35 (8): 853–62. doi:10.1111/j.1365-2230.2010.03826.x. PMID 20456393. S2CID 1477097.
Majumdar S, Mockenhaupt M, Roujeau JC, Townshend AP (2002-10-21). "Interventions for toxic epidermal necrolysis". Cochrane Database of Systematic Reviews. 2015 (4): CD001435. doi:10.1002/14651858.CD001435. ISSN 1465-1858. PMC 8958873. PMID 12519556. Archived from the original on 2018-06-25. Retrieved 2018-06-25.
Quinn AM, Brown K, Bonish BK, Curry J, Gordon KB, Sinacore J, Gamelli R, Nickoloff BJ, et al. (2005). "Uncovering histological criteria with prognostic significance in toxic epidermal necrolysis". Arch Dermatol. 141 (6): 683–7. doi:10.1001/archderm.141.6.683. PMID 15967913.
Schwartz RA, McDonough, PH, Lee, BW (August 2013). "Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment". Journal of the American Academy of Dermatology. 69 (2): 187.e1–16, quiz 203–4. doi:10.1016/j.jaad.2013.05.002. PMID 23866879.

ncbi.nlm.nih.gov

Adler NR, Aung AK, Ergen EN, Trubiano J, Goh MS, Phillips EJ (2017). "Recent advances in the understanding of severe cutaneous adverse reactions". The British Journal of Dermatology. 177 (5): 1234–1247. doi:10.1111/bjd.15423. PMC 5582023. PMID 28256714.
McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperavičiūtė D, Carrington M, Sills GJ, Marson T, Jia X, de Bakker PI, Chinthapalli K, Molokhia M, Johnson MR, O'Connor GD, Chaila E, Alhusaini S, Shianna KV, Radtke RA, Heinzen EL, Walley N, Pandolfo M, Pichler W, Park BK, Depondt C, Sisodiya SM, Goldstein DB, Deloukas P, Delanty N, Cavalleri GL, Pirmohamed M (24 March 2011). "HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans". The New England Journal of Medicine. 364 (12): 1134–43. doi:10.1056/nejmoa1013297. PMC 3113609. PMID 21428769.
Alfirevic A, Pirmohamed M, Marinovic B, Harcourt-Smith L, Jorgensen AL, Cooper TE (17 July 2019). "Genetic testing for prevention of severe drug-induced skin rash". Cochrane Database of Systematic Reviews. 2019 (7): CD010891. doi:10.1002/14651858.CD010891.pub2. PMC 6636675. PMID 31314143.
Majumdar S, Mockenhaupt M, Roujeau JC, Townshend AP (2002-10-21). "Interventions for toxic epidermal necrolysis". Cochrane Database of Systematic Reviews. 2015 (4): CD001435. doi:10.1002/14651858.CD001435. ISSN 1465-1858. PMC 8958873. PMID 12519556. Archived from the original on 2018-06-25. Retrieved 2018-06-25.

ghr.nlm.nih.gov

"Stevens-Johnson syndrome/toxic epidermal necrolysis". Genetics Home Reference. July 2015. Archived from the original on 27 April 2017. Retrieved 26 April 2017.

rarediseases.info.nih.gov

"Stevens-Johnson syndrome". GARD. Archived from the original on 28 August 2016. Retrieved 26 August 2016.

orpha.net

"Orphanet: Toxic epidermal necrolysis". Orphanet. November 2008. Archived from the original on 27 April 2017. Retrieved 26 April 2017.

semanticscholar.org

api.semanticscholar.org

Maverakis E, Wang EA, Shinkai K, Mahasirimongkol S, Margolis DJ, Avigan M, Chung WH, Goldman J, Grenade LL (2017-06-01). "Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Standard Reporting and Evaluation Guidelines: Results of a National Institutes of Health Working Group" (PDF). JAMA Dermatology. 153 (6): 587–592. doi:10.1001/jamadermatol.2017.0160. ISSN 2168-6068. PMID 28296986. S2CID 205110875. Archived (PDF) from the original on 2019-12-03. Retrieved 2019-12-12.
Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, Hu SL, Wu MT, Chen GS, Wong TW, Hsiao PF, Chen WH, Shih HY, Fang WH, Wei CY, Lou YH, Huang YL, Lin JJ, Chen YT (April 2006). "Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions". Pharmacogenetics and Genomics. 16 (4): 297–306. doi:10.1097/01.fpc.0000199500.46842.4a. PMID 16538176. S2CID 45667604.
Tohkin M, Kaniwa N, Saito Y, Sugiyama E, Kurose K, Nishikawa J, Hasegawa R, Aihara M, Matsunaga K, Abe M, Furuya H, Takahashi Y, Ikeda H, Muramatsu M, Ueta M, Sotozono C, Kinoshita S, Ikezawa Z, Japan Pharmacogenomics Data Science C (February 2013). "A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients". The Pharmacogenomics Journal. 13 (1): 60–9. doi:10.1038/tpj.2011.41. PMID 21912425. S2CID 42286060.
Zajicek R, Pintar D, Broz L, Suca H, Königova R (May 2012). "Toxic epidermal necrolysis and Stevens-Johnson syndrome at the Prague Burn Centre 1998-2008". Journal of the European Academy of Dermatology and Venereology. 26 (5): 639–43. doi:10.1111/j.1468-3083.2011.04143.x. PMID 21668825. S2CID 25253929.
Rajaratnam R, Mann C, Balasubramaniam P, et al. (December 2010). "Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centre". Clin. Exp. Dermatol. 35 (8): 853–62. doi:10.1111/j.1365-2230.2010.03826.x. PMID 20456393. S2CID 1477097.

uzh.ch

zora.uzh.ch

Maverakis E, Wang EA, Shinkai K, Mahasirimongkol S, Margolis DJ, Avigan M, Chung WH, Goldman J, Grenade LL (2017-06-01). "Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Standard Reporting and Evaluation Guidelines: Results of a National Institutes of Health Working Group" (PDF). JAMA Dermatology. 153 (6): 587–592. doi:10.1001/jamadermatol.2017.0160. ISSN 2168-6068. PMID 28296986. S2CID 205110875. Archived (PDF) from the original on 2019-12-03. Retrieved 2019-12-12.

web.archive.org

"Stevens-Johnson syndrome/toxic epidermal necrolysis". Genetics Home Reference. July 2015. Archived from the original on 27 April 2017. Retrieved 26 April 2017.
"Orphanet: Toxic epidermal necrolysis". Orphanet. November 2008. Archived from the original on 27 April 2017. Retrieved 26 April 2017.
"Stevens-Johnson syndrome". GARD. Archived from the original on 28 August 2016. Retrieved 26 August 2016.
Maverakis E, Wang EA, Shinkai K, Mahasirimongkol S, Margolis DJ, Avigan M, Chung WH, Goldman J, Grenade LL (2017-06-01). "Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Standard Reporting and Evaluation Guidelines: Results of a National Institutes of Health Working Group" (PDF). JAMA Dermatology. 153 (6): 587–592. doi:10.1001/jamadermatol.2017.0160. ISSN 2168-6068. PMID 28296986. S2CID 205110875. Archived (PDF) from the original on 2019-12-03. Retrieved 2019-12-12.
Garra, GP (2007). "Toxic Epidermal Necrolysis Archived 2007-12-27 at the Wayback Machine". Emedicine.com. Retrieved on December 13, 2007.
Majumdar S, Mockenhaupt M, Roujeau JC, Townshend AP (2002-10-21). "Interventions for toxic epidermal necrolysis". Cochrane Database of Systematic Reviews. 2015 (4): CD001435. doi:10.1002/14651858.CD001435. ISSN 1465-1858. PMC 8958873. PMID 12519556. Archived from the original on 2018-06-25. Retrieved 2018-06-25.

worldcat.org

search.worldcat.org

Maverakis E, Wang EA, Shinkai K, Mahasirimongkol S, Margolis DJ, Avigan M, Chung WH, Goldman J, Grenade LL (2017-06-01). "Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Standard Reporting and Evaluation Guidelines: Results of a National Institutes of Health Working Group" (PDF). JAMA Dermatology. 153 (6): 587–592. doi:10.1001/jamadermatol.2017.0160. ISSN 2168-6068. PMID 28296986. S2CID 205110875. Archived (PDF) from the original on 2019-12-03. Retrieved 2019-12-12.
Majumdar S, Mockenhaupt M, Roujeau JC, Townshend AP (2002-10-21). "Interventions for toxic epidermal necrolysis". Cochrane Database of Systematic Reviews. 2015 (4): CD001435. doi:10.1002/14651858.CD001435. ISSN 1465-1858. PMC 8958873. PMID 12519556. Archived from the original on 2018-06-25. Retrieved 2018-06-25.